Latest Deals
Bayer has sold a stake of its contraceptive business to Apollo. Credit: OleksSH/Shutterstock.com
Bayer banks €3bn in Apollo contraceptives division deal
Bayer has sold a stake in its contraceptives offshoot to Apollo for €3bn ($3.4bn) – allowing the company to access funds without relinquishing overall control of the business. Apollo will secure a minority, stake in the German life sciences giant’s long-acting reversible contraceptives business, which will house the company’s marketed options such as hormonal intrauterine devices, Mirena, Jaydess and Kyleena, as well as upper arm-based implant, Jadelle.
Lilly enters psychedelic realm through $2.8bn AtaiBeckley takeover
Following its high-profile dealmaking spree in the first portion of 2026, Eli Lilly has struck again – this time through a multi-billion-dollar acquisition of psychedelic biotech, AtaiBeckley. Through the deal, which will set Lilly back $2.8bn upfront, the pharmaceutical giant will absorb AtaiBeckley’s three-strong clinical-stage pipeline – including nasally administered treatment-resistant depression candidate, BPL-003.
Samsung Biologics to acquire PolyPeptide in $1.81bn cash deal
Samsung Biologics is set to acquire PolyPeptide Group through an all-cash public tender offer valued at SFr1.46bn ($1.81bn). The proposed offer is set at SFr44.31 per share for 100% of PolyPeptide’s fully diluted share capital, excluding treasury shares. Completion of the deal is anticipated towards the end of this year.
AstraZeneca pays up to $1.5bn to license Dizal Pharma’s lung cancer drug
AstraZeneca has acquired the global rights to Dizal Pharmaceutical’s Zegfrovy (sunvozertinib), marking the drugmaker’s second venture to China in a month in search of new assets. As per the license agreement, AstraZeneca will pay an upfront fee of $600m, with a further $900m to follow if specific development, regulatory and sales-related milestones are met.
